Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

891
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
891
iPS Cell Differentiation01:22

iPS Cell Differentiation

3.0K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.0K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.0K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Outcomes and Predictors of Retinal Breaks in Patients With Vitreous Hemorrhage Secondary to a Posterior Vitreous Detachment.

Journal of vitreoretinal diseases·2026
Same author

RPE With ROCK-Mediated Epithelial-Mesenchymal Transition as a Key Contributor of Subretinal Fibrosis in AMD.

Investigative ophthalmology & visual science·2026
Same author

Comparability of aflibercept biosimilar with reference aflibercept in diabetic macular edema: subgroup analysis of the pivotal Phase-III INSIGHT randomized clinical trial.

Expert opinion on biological therapy·2026
Same author

Aberrant retinal structure and vasculature in mouse models of dominant retinopathies caused by <i>CRX</i> homeodomain mutations.

bioRxiv : the preprint server for biology·2026
Same author

Energetic diversity in retinal ganglion cells is modulated by neuronal activity and correlates with resilience to degeneration.

Nature communications·2026
Same author

Neuroimaging Biomarkers of Disease Progression and Cognitive Change in Patients With Retinal Vasculopathy With Cerebral Leukoencephalopathy.

Neurology·2026
Same journal

Whole-cell particle-based digital twin simulations from 4D lattice light-sheet microscopy data.

Cell·2026
Same journal

Systematic discovery of pathogen effector functions across human pathogens and pathways.

Cell·2026
Same journal

Structural basis for host membrane binding and remodeling by invading malaria parasites.

Cell·2026
Same journal

Multiscale integration of tissue and chromatin context converts cell heterogeneity into stable intestinal patterning.

Cell·2026
Same journal

Arc mediates intercellular tau transmission via extracellular vesicles.

Cell·2026
Same journal

Geometric constraints on the architecture of mammalian cortical connectomes.

Cell·2026
See all related articles

Related Experiment Video

Updated: Dec 25, 2025

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
10:24

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

10.6K

Reducing Treatment Burden in AMD.

Rajendra S Apte1

  • 1Paul A. Cibis Distinguished Professor, Washington University in St. Louis School of Medicine, St. Louis, MO, USA.

Cell
|March 24, 2020
PubMed
Summary
This summary is machine-generated.

Vascular Endothelial Growth Factor-A (VEGF-A) antagonists offer new hope for wet age-related macular degeneration (AMD). Brolucizumab shows comparable visual results and better anatomic outcomes than aflibercept, reducing treatment burden.

More Related Videos

Author Spotlight: Unraveling the Pathogenesis of Age-Related Macular Degeneration and Discovering Potential Therapies
06:16

Author Spotlight: Unraveling the Pathogenesis of Age-Related Macular Degeneration and Discovering Potential Therapies

Published on: July 28, 2023

3.0K
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.4K

Related Experiment Videos

Last Updated: Dec 25, 2025

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
10:24

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

10.6K
Author Spotlight: Unraveling the Pathogenesis of Age-Related Macular Degeneration and Discovering Potential Therapies
06:16

Author Spotlight: Unraveling the Pathogenesis of Age-Related Macular Degeneration and Discovering Potential Therapies

Published on: July 28, 2023

3.0K
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.4K

Area of Science:

  • Ophthalmology
  • Medical Research
  • Drug Development

Background:

  • Vascular Endothelial Growth Factor-A (VEGF-A) antagonists have transformed wet age-related macular degeneration (AMD) treatment.
  • Persistent wet AMD necessitates frequent intraocular injections, posing a significant treatment burden.

Purpose of the Study:

  • To compare the efficacy of brolucizumab, a direct VEGF-A inhibitor, with aflibercept in treating wet AMD.
  • To evaluate visual and anatomic outcomes, including retinal fluid reduction.

Main Methods:

  • Brolucizumab directly inhibits VEGF-A.
  • Comparison of visual acuity and retinal fluid measurements between brolucizumab and aflibercept treatment groups.

Main Results:

  • Brolucizumab demonstrated visual outcomes comparable to aflibercept.
  • Anatomic outcomes, specifically reduced retinal fluid, favored brolucizumab.

Conclusions:

  • Brolucizumab represents a promising therapeutic option for wet AMD.
  • Direct VEGF-A inhibition with brolucizumab may offer improved anatomic control and potentially reduce treatment burden.